2021 News

Stay up to date on all that’s happening at Santen USA. For our global headquarters news, visit Santen Worldwide.

News

Santen Reports 2nd Quarter Fiscal 2021 Performance
Verkazia (cyclosporine 0.1%) for the Treatment of Severe Vernal Keratoconjunctivitis is Now Reimbursed by Non-Insured Health Benefits (NIHB) Program
Verkazia (cyclosporine 0.1%) for the Treatment of Severe Vernal Keratoconjunctivitis is now Publicly Reimbursed in New Brunswick
Santen Receives FDA Approval for Verkazia™ (Cyclosporine Ophthalmic Emulsion) 0.1% for the Treatment of Vernal Keratoconjunctivitis in Children and Adults
Santen Announces Medium-Term Plan (MTP2025)
Santen and Glaukos Enter into a New Collaboration in the Development and Commercialization of STN2000100 (DE-128) in the Americas, Australia, and New Zealand
Santen Reports Consolidated Results for Fiscal 2020
Santen Announces Health Canada Approval of PRESERFLO MicroShunt
Santen Announces Global Research Initiative with Massachusetts Eye and Ear and Ulster University Researchers to Study and Develop New Treatments for Glaucoma
Verkazia for the Treatment of Severe Vernal Keratoconjunctivitis is now Publicly Reimbursed in Ontario under the Exceptional Access Program
Verkazia for the Treatment of Severe Vernal Keratoconjunctivitis is now Publicly Reimbursed in Quebec
Santen Reports 3rd Quarter Fiscal 2020 Performance
Santen and Ube Announces U.S. FDA Acceptance of New Drug Application for STN10117 (DE-117) Omidenepag Isopropyl as a Treatment for Patients with Glaucoma and Ocular Hypertension
News Archive
Copyright © 2023 Santen Pharmaceutical Co., Ltd.
All Rights Reserved